Takeda Pharmaceutical plans to eliminate approximately 4,500 jobs globally. These cuts are part of a major "Transformation Program" by March 2027. The restructuring aims to consolidate departments and automate operations. This effort follows the significant revenue decline of its dr-g VYVANSE. Savings will fund new experimental dr-g launches for future growth.
https://finance.yahoo.com/sectors/healthcare/articles/takeda-laying-off-4-500-204550228.html